TOV:MYX Declaration of Unacceptable Circumstances and Orders
Released
Released
Announcement PDF
MEDIA RELEASE
1/11
No: TP25/096
Wednesday, 19 November 2025
Mayne Pharma Group Limited – Declaration of Unacceptable Circumstances and
Orders
The Panel has made a declaration of unacceptable circumstances (Annexure A) in
relation to an application dated 6 November 2025 by Mayne Pharma Group Limited
in relation to its own affairs (see TP25/093 and TP25/095).
The Panel has also made final orders (Annexure B) including orders requiring
Cosette Pharmaceuticals, Inc. to agree to any conditions reasonably required by the
Treasurer (in relation to FIRB approval) in connection with the Salisbury Site
(including conditions reasonably restraining its closure) that are not inconsistent
with Cosette’s prior intentions disclosure in the Scheme Booklet.
The Panel considered that Cosette’s change of intentions in relation to the Salisbury
Site means that the market for control of Mayne Pharma is not proceeding in a
manner generally expected for schemes and is contrary to an efficient, competitive
and informed market. The Panel also considered that during the period between 24
June 2025 and 8 September 2025, the market was uninformed of Cosette’s change of
intentions in relation to the Salisbury Site.
While this decision is specific to its facts, when considering the public interest, the
Panel took into account the concerns raised by the application regarding the ability
for bidders to use a change of intention or similar strategies to potentially defeat
transactions in a way that is contrary to the efficient, competitive and informed
market principle in the Corporations Act 2001 (Cth).
Background
Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed pharmaceuticals
company (ASX: MYX). Mayne Pharma’s business is predominantly US-based.
However, it also has a presence in Australia, including a manufacturing site in
Salisbury, South Australia (the Salisbury Site), which employs over 200 people.
Mayne Pharma entered into a scheme implementation deed (SID) with Cosette
Pharmaceuticals, Inc. (Cosette) in relation to the acquisition of all of the shares in
Mayne Pharma for $7.40 cash per share by way of scheme of arrangement (Scheme),
2/11
subject to certain conditions precedent, including that no “Mayne Material Adverse
Change”1 (MAC) occurs and that Cosette receives the Treasurer’s approval under the
Foreign Acquisitions and Takeovers Act (FIRB Approval).
On 15 May 2025, Cosette released an explanatory statement in relation to the Scheme
(Scheme Booklet) which stated, subject to certain qualifications, that Cosette
intended to (among other things): “continue the business and operations of Mayne
Pharma largely in the same manner as it is currently operated and to investigate
opportunities to integrate and grow Mayne Pharma’s business;… and retain Mayne
Pharma’s existing employees to the extent it is commercially appropriate to do so…”.
Cosette’s application for FIRB Approval included substantially similar disclosure as
the Scheme Booklet in relation to Cosette’s intentions.
On and after 17 May 2025, Cosette served termination notices upon Mayne Pharma,
including alleging that the MAC had been triggered, that Mayne Pharma had
breached its continuous disclosure obligations, and that Mayne Pharma had misled
Cosette into entering into the SID (Termination Notices). Mayne Pharma
subsequently commenced court proceedings in respect of the Termination Notices.
On 18 June 2025, Mayne Pharma shareholders voted in favour of the Scheme at the
scheme meeting.
On 24 June 2025, Cosette made a communication to FIRB to the effect that it had re-
evaluated its intentions concerning Mayne Pharma’s business in Australia and
determined that “its current intention is to seek to dispose of or close” the Salisbury Site.
Cosette provided Mayne Pharma with a copy of this communication on the same
day.
On 8 September 2025, following media reports that South Australia’s Premier had
intervened in the FIRB process, Mayne Pharma made an ASX announcement which
(among other things) disclosed Cosette’s change of intentions in relation to the
Salisbury Site.
On 15 October 2025, the Court determined that no MAC had occurred and
accordingly the Termination Notices were invalid and the SID remains valid and on
foot.
On 30 October 2025, Cosette received a letter from the Treasurer which referred to
Cosette’s change of intentions in relation to the Salisbury Site and stated (among
other things) that the Treasurer was of the preliminary view that the proposed
1 Being (other than certain excepted events) “[a]ny event, occurrence, change, circumstance or matter…
which has, has had or is (either individually or when aggregated together with any such other events,
occurrences, changes matters or circumstances) reasonably expected to have, the effect of diminishing the
consolidated Maintainable EBITDA over a 12-month period of the Mayne Group, taken as a whole, by at least
A$10.76 million…”
3/11
acquisition would be contrary to the national interest and that he was “considering
whether he should make orders prohibiting the acquisition contemplated by the Scheme”.
For more details, see paragraphs 1 to 16 of the Declaration.
Declaration
The Panel considers that it was reasonable for Mayne Pharma shareholders and the
market generally to expect that the matters contained in the Termination Notices
would not result in a re-evaluation of Cosette’s intentions in relation to the Salisbury
Site (except as qualified in the Scheme Booklet) prior to implementation of the
scheme, particularly given that:
• the matters contained in the Termination Notices were known before orders
were made approving the convening of the scheme meeting
• Mayne Pharma shareholders voted on the Scheme and the market traded on the
basis that any review of Cosette’s intentions would occur “after implementation of
the Scheme” and
• the Court has determined that no MAC had occurred and accordingly the
Termination Notices were invalid and the SID remains valid and on foot.
The Panel also considers that:
• It was at least foreseeable to Cosette that its change of intentions in relation to
the Salisbury Site put the prospects of receiving FIRB Approval (and
consequently, the prospects of the Scheme being implemented) at risk.
• Cosette’s change of intentions in relation to the Salisbury Site means that the
market for control of Mayne Pharma is not proceeding in a manner generally
expected for schemes and is contrary to an efficient, competitive and informed
market.
• During the period between 24 June 2025 and 8 September 2025, the market was
uninformed of Cosette’s change of intentions in relation to the Salisbury Site.
Orders
The Panel made orders including that Cosette must agree to any conditions
reasonably required by the Treasurer in connection with the Salisbury Site (including
conditions reasonably restraining its closure) that are not inconsistent with Cosette’s
prior intentions disclosure in the Scheme Booklet.
The sitting Panel was Yasmin Allen AM (sitting President), Michael Borsky KC and
Richard Phillips.
4/11
The Panel will publish its reasons for the decision in due course on its website
www.takeovers.gov.au.
Allan Bulman
Chief Executive, Takeovers Panel
Level 16, 530 Collins Street
Melbourne VIC 3000
Ph: +61 3 9655 3500
takeovers@takeovers.gov.au
5/11
ANNEXURE A
CORPORATIONS ACT
SECTION 657A
DECLARATION OF UNACCEPTABLE CIRCUMSTANCES
MAYNE PHARMA GROUP LIMITED
BACKGROUND
1. Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed
pharmaceuticals company (ASX: MYX). Its business is predominantly US-
based. However, it also has a presence in Australia, including a manufacturing
site in Salisbury, South Australia (the Salisbury Site), which employs in excess
of 200 people.
2. Cosette Pharmaceuticals, Inc. (Cosette) is the main operating entity of the
Cosette group, a US-based pharmaceuticals group.2
3. On 20 February 2025, Mayne Pharma entered into a scheme implementation
deed (SID) with Cosette in relation to the acquisition of all of the shares in
Mayne Pharma for $7.40 cash per share by way of scheme of arrangement
(Scheme), subject to certain conditions precedent, including that no “Mayne
Material Adverse Change” (MAC) occurs and that Cosette receives the
Treasurer’s approval under the Foreign Acquisitions and Takeovers Act (FIRB
Approval). The SID is subject to an “End Date” of 24 November 2025, unless
extended by agreement between the parties.3
4. On 25 February 2025, Cosette lodged an application with the Foreign
Investment Review Board (FIRB) seeking FIRB Approval.
5. On 15 May 2025, the first court hearing in relation to the Scheme occurred, at
which both Mayne Pharma and Cosette appeared and at which orders were
made approving the convening of the scheme meeting and approving
2
Cosette and Cosette Australia BidCo Pty Ltd are each wholly owned subsidiaries of Cosette Pharmaceuticals
Holdings, Inc., which is jointly owned and controlled by Avista Capital Holdings LP and Hamilton Lane
Advisors LLC
3
Pursuant to the Panel’s interim orders dated 14 November 2025 which (in effect) extended the End Date from
20 November 2025 to 24 November 2025
6/11
distribution of the explanatory statement in relation to the Scheme (Scheme
Booklet).
6. Also on 15 May 2025, Mayne Pharma released the Scheme Booklet. The Scheme
Booklet included information provided by Cosette, including the following
statements in Section 8 in respect of Cosette’s intentions:
(a) “If the Scheme is implemented, the Cosette Group’s current intention is to
continue the business and operations of Mayne Pharma largely in the same
manner as it is currently operated and to investigate opportunities to integrate
and grow Mayne Pharma’s business (which may include further investment
flowing to Mayne Pharma).”4
(b) “Following implementation of the Scheme, the Cosette Group will review Mayne
Pharma’s business operations and organisational structure to ensure that the
combined Mayne Pharma Group and Cosette Group has the appropriate mix and
level of employees and skills to enhance the business going forward and enable it
to pursue growth opportunities.
The Cosette Group’s current intention is to retain Mayne Pharma’s existing
employees to the extent that it is commercially appropriate to do so.”5
(c) “The statements in this Section 8 (Information on Cosette and Cosette Group)
regarding the Cosette Group’s intentions are based on information concerning the
Mayne Pharma Group and the general business environment which are known to
the Cosette Group at the time of the preparation of this Scheme Booklet. After
implementation of the Scheme, the Cosette Group may conduct a review of Mayne
Pharma and its operations, assets, liabilities, structure and employees, following
which it may, as required, review its intentions as set out in this Section. Final
decisions regarding these matters will be made in light of all material information,
facts and circumstances at the relevant time if the Scheme is implemented.
Accordingly, it is important to recognise that the statements set out in this
Section 8 are statements of current intention only and may change as new
information becomes available or circumstances change.”6
(d) “The Cosette Group refers to the announcements made by Mayne Pharma to ASX
on 14 May 2025 as referred to in Section 7.10 [in relation to a letter from the
FDA]. The matters described in these announcements remain under consideration
by the Cosette Group as at the date of this Scheme Booklet, including in relation to
the impact of these matters on Mayne Pharma and its business and operations.”7
(e) “Other than as disclosed in this Section 8 (Information on Cosette and Cosette
Group), there is no information regarding the Cosette Group or its intentions
4
At Section 8.3(b)
5
At Section 8.3(d)
6
At Section 8.3(a)
7
At Section 8.4(f)
7/11
regarding Mayne Pharma, that is material to the making of a decision by a Mayne
Pharma Shareholder on whether or not to vote in favour of the Scheme that is
within the knowledge of any director of Cosette or Cosette Sub as at the date of
this Scheme Booklet that has not been previously disclosed to Mayne Pharma
Shareholders.”8
7. Cosette’s application with FIRB referred to in paragraph 4 included
substantially similar disclosure in relation to Cosette’s intentions as set out in
paragraph 6.
8. On 17 May 2025, Cosette served a notice on Mayne Pharma seeking to assert
that a MAC had occurred. Cosette subsequently issued four termination
notices upon Mayne Pharma, including alleging that the MAC had been
triggered, that Mayne Pharma had breached its continuous disclosure
obligations and that Mayne Pharma had misled Cosette into entering into the
SID (Termination Notices).
9. On 4 June 2025, Mayne Pharma commenced proceedings in respect of the
Termination Notices in the Supreme Court of New South Wales (Court) seeking
orders that Cosette had not validly terminated the SID.
10. On 5 June 2025, Mayne Pharma released a supplementary scheme booklet
containing disclosure in relation to (among other things) the Termination
Notices and the Court proceedings in respect of them.
11. On 18 June 2025, Mayne Pharma shareholders voted in favour of the Scheme at
the scheme meeting.
CIRCUMSTANCES
12. On 24 June 2025, Cosette made a communication to FIRB to the effect that it had
re-evaluated its intentions concerning Mayne Pharma’s business in Australia
and determined that “its current intention is to seek to dispose of or close” the
Salisbury Site. Cosette provided Mayne Pharma with a copy of this
communication on the same day.
13. The factors relevant to Cosette’s update to its intentions, as submitted by
Cosette, included the matters contained in the Termination Notices as well as
other factors including that the Australian operations were not material to
Mayne Pharma’s overall operations and significantly less material in the context
of the combined business.
8
At Section 8.4(f)
8/11
14. On 8 September 2025, following media reports that South Australia’s Premier
had intervened in the FIRB process, Mayne Pharma announced (among other
things) the following:
“Mayne Pharma is aware that, since Cosette’s purported termination of the
Scheme, Cosette has had some correspondence with FIRB in respect of its
intentions for the Mayne Pharma business (including possible intentions to either
close or sell the Salisbury site) following implementation of the Scheme, should
Cosette’s attempts to terminate, or otherwise get out of its obligations under, the
SID, fail.”
15. On 15 October 2025, the Court determined that no MAC had occurred and
accordingly the Termination Notices were invalid and the SID remains valid
and on foot.
16. On 31 October 2025, Mayne Pharma announced an update on the status of FIRB
Approval following the receipt of a letter from the Treasurer to Cosette dated 30
October 2025, including as follows:
“Mayne Pharma has been provided by Cosette with a letter received from the
Treasurer indicating that his “preliminary view is that the Proposed Acquisition
would be contrary to the national interest, on the grounds that it would
negatively impact the Australian economy and community”. The letter states that
the Treasurer is considering whether he should make orders prohibiting the
acquisition contemplated by the Scheme.
The letter specifically refers to the fact that on 24 June 2025 … the “Treasury was
advised that Cosette had re-evaluated its intentions concerning Mayne Pharma’s
business in Australia and determined that if Cosette were to acquire Mayne
Pharma, its current intention is to seek to dispose of, or close, the manufacturing
site in Adelaide” and goes on to detail the Treasurer’s view as to the importance of
that site to Australia’s pharmaceutical manufacturing and research and
development capabilities. The letter does not point to any other basis for the
Treasurer’s preliminary view…“
EFFECT
17. The Panel considers that it was reasonable for Mayne Pharma shareholders and
the market generally to expect that the matters contained in the Termination
Notices would not result in a re-evaluation of Cosette’s intentions in relation to
the Salisbury Site9 prior to implementation of the Scheme, particularly given
that:
(a) the matters contained in the Termination Notices were known before
orders were made approving the convening of the scheme meeting
9
Except as qualified, see paragraphs 6(c) and 6(d)
9/11
(b) Mayne Pharma shareholders voted on the Scheme and the market traded
on the basis that any review of Cosette’s intentions would occur “after
implementation of the Scheme” and
(c) the Court has determined that no MAC had occurred and accordingly the
Termination Notices were invalid and the SID remains valid and on foot.
18. The Panel considers that it was at least foreseeable to Cosette that its change of
intentions in relation to the Salisbury Site put the prospects of receiving FIRB
Approval (and consequently, the prospects of the Scheme being implemented)
at risk.
19. Cosette’s change of intentions in relation to the Salisbury Site means that the
market for control of Mayne Pharma is not proceeding in a manner generally
expected for schemes and is contrary to an efficient, competitive and informed
market.
20. During the period between 24 June 2025 and 8 September 2025, the market was
uninformed of Cosette’s change of intentions in relation to the Salisbury Site.
CONCLUSION
21. It appears to the Panel that the circumstances are unacceptable circumstances:
(a) having regard to the effect that the Panel is satisfied they have had, are
having, will have or are likely to have on the control, or potential control,
of Mayne Pharma or
(b) having regard to the purposes of Chapter 6 set out in section 602 of the
Corporations Act 2001 (Cth) (Act).
22. The Panel considers that it is not against the public interest to make a
declaration of unacceptable circumstances. It has had regard to the matters in
section 657A(3) of the Act.
DECLARATION
The Panel declares that the circumstances constitute unacceptable circumstances in
relation to the affairs of Mayne Pharma.
Tania Mattei
General Counsel
with authority of Yasmin Allen AM
President of the sitting Panel
Dated 19 November 2025
10/11
ANNEXURE B
CORPORATIONS ACT
SECTION 657D
ORDERS
MAYNE PHARMA GROUP LIMITED
The Panel made a declaration of unacceptable circumstances on 19 November 2025.
THE PANEL ORDERS
1. Cosette must agree to any conditions reasonably required by the Treasurer in
connection with the Salisbury Site (including conditions reasonably restraining
its closure) that are not inconsistent with Cosette’s prior intentions disclosure in
the Scheme Booklet.
2. Each of Cosette and Mayne Pharma must provide, and consent to the disclosure
of, all communications between the Foreign Investment Review Board and that
party in connection with the foreign investment application made by Cosette on
or about 25 February 2025, to the other party immediately upon issue or receipt
of such communications, provided that each party is entitled to redact or not
disclose any part of that communication which contains or constitutes
competitively sensitive or privileged information relating to that party.
3. The definition of “End Date” as defined in and for the purposes of (as
applicable) the Scheme Implementation Deed, Scheme and Deed Poll is
amended to read as per the definition of End Date in these orders.
Interpretation
4. In these orders, capitalised terms have the meaning given to them in the
Scheme Implementation Deed unless defined below.
Cosette Cosette Pharmaceuticals, Inc.
Cosette Sub Cosette Australia BidCo Pty Ltd
Deed Poll The Deed Poll executed by Cosette and Cosette
Sub in favour of the Scheme Shareholders dated 9
May 2025
11/11
End Date 24 November 2025 or such other date as may be
agreed in writing between Mayne Pharma and
Cosette
Mayne Pharma Mayne Pharma Group Limited
Salisbury Site Mayne Pharma’s manufacturing site in Salisbury,
South Australia
Scheme The members’ scheme of arrangement under Part
5.1 of the Corporations Act between Mayne
Pharma and the Scheme Shareholders under which
all of the Scheme Shares will be transferred to
Cosette Sub and the Scheme Shareholders will be
entitled to receive the Scheme Consideration, in the
form attached to the Scheme Booklet, together with
any alterations or conditions made or required by
the Court under section 411(6) of the Corporations
Act and agreed to by Mayne Pharma and Cosette
(or Cosette Sub as applicable)
Scheme Booklet The explanatory statement released by Mayne
Pharma to ASX on 15 May 2025
Scheme
Implementation
Deed
The Scheme Implementation Deed dated 20
February 2025 between Mayne Pharma and
Cosette (as amended from time to time)
Tania Mattei
General Counsel
with authority of Yasmin Allen AM
President of the sitting Panel
Dated 19 November 2025
Share your feedback
Discover